InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.64
(
0.00%
)
US TECH 100
19,032.80
(
-0.91%
)
Dow Jones
39,415.88
(
0.68%
)
Brent Oil
85.33
(
1.55%
)
Bitcoin
60,195.55
(
-4.69%
)
Post# of 252321
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 90683

Wednesday, 04/21/2010 2:25:06 AM

Wednesday, April 21, 2010 2:25:06 AM

Post# of 252321
Updated for Tysbari 1Q10 sales as reported yesterday by BIIB:

In the first quarter global sales of Tysabri rose 28 percent to $292 million.
As of the end of March, about 50,300 patients were on commercial and clinical Tysabri therapy worldwide. That compares with a figure of 48,800 patients as of the end of 2009.

http://uk.finance.yahoo.com/news/update-2-biogen-profit-falls-on-charges-tysabri-sales-rise-targetukfocus-e2ed5943dbeb.html
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up